Viyash Scientific Ltd Board of Directors
Board of Directors at Viyash Scientific Ltd
Non-Exec & Non-Independent Dir
Non-Exec & Non-Independent Dir
Non Executive Director
Chairman & Independent Directo
Non-Exec. & Independent Dir.
Key Highlights
- Kamal K Sharma joins the board as Chairman & Independent Directo, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Milind Sarwate joins the board as Independent Non Exe. Director, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Revati Kasture joins the board as Independent Non Exe. Director, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Anuj Poddar joins the board as Non-Exec & Non-Independent Dir, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Hari Babu Bodepudi joins the board as Group CEO & Executive Director, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
Viyash Scientific Ltd
NSE: VIYASH
Share Price
Last Ten Days Market Price
| Date | |
|---|---|
| 06 Oct 2026 | 233.5 |
| 05 Oct 2026 | 229.25 |
| 01 Oct 2026 | 231.8 |
| 30 Sep 2026 | 235.85 |
| 29 Sep 2026 | 238.05 |
| 28 Sep 2026 | 240.8 |
| 25 Sep 2026 | 244.45 |
| 24 Sep 2026 | 246.05 |
| 23 Sep 2026 | 253.65 |
| 22 Sep 2026 | 251.55 |
Company Fundamentals for Viyash Scientific Ltd
Market Cap
10,312 Cr
EPS
5.1
P/E Ratio (TTM)
46.0
P/B Ratio (TTM)
3.7
Day’s High
234.5
Day’s Low
228.25
DTE
0.2
ROE
7.1
52 Week High
297.9
52 Week Low
178.4
ROCE
13.0
Market Price of Viyash Scientific Ltd
1M
1Y
3Y
5Y
Viyash Scientific Ltd News Hub
Sequent Scientific receives WHO prequalification approval for Albendazole API
Sequent Scientific announced its receipt of prequalification (PQ) approval from the World Health Org
Read more
20 Aug 24
Sequent Scientific hits 52-week high after receiving prequalification approval for Albendazole
This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialise
Read more
20 Aug 24
Sequent Scientific reports consolidated net profit of Rs 6.51 crore in the June 2024 quarter
Net profit of Sequent Scientific reported to Rs 6.51 crore in the quarter ended June 2024 as against
Read more
16 Aug 24
Sequent Scientific to table results
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 14 August 2024. P
Read more
09 Aug 24
